TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27835716

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment for 8 weeks
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo (saline) treatment
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment for patients with objective memory dysfunction at baseline (n = 16)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment
Number of subjects: 79
Study: 24867313

Group type: EXPERIMENTAL
Intervention: ETDRS charts
Number of subjects: 75

Group type: COMPARATOR
Intervention: Landolt C test
Number of subjects: 75
Study: 21847713

Group type: COMPARATOR
Intervention: 0 g/day RPM
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 2.5 g/day RPM
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 3.5 g/day RPM
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 4.5 g/day RPM
Number of subjects: 16
Study: 20303474

Group type: EXPERIMENTAL
Intervention: 250 mg single oral dose of D-cycloserine (DCS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18777201

Group type: EXPERIMENTAL
Intervention: Paper-based EQ VAS (20 cm vertical)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Touch-screen EQ VAS (horizontal)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Comparison of both modes
Number of subjects: 314
Study: 16189520

Group type: EXPERIMENTAL
Intervention: Primary hrHPV screening
Number of subjects: 14149

Group type: COMPARATOR
Intervention: Cytology triage
Number of subjects: 14149
Study: 12235506

Group type: EXPERIMENTAL
Intervention: HERMES-assisted laparoscopic operations
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard laparoscopic operations (non-HERMES)
Number of subjects: 30
Study: 9698813

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 5 mg/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study: 7894879

Group type: EXPERIMENTAL
Intervention: Amisulpride 100 mg/d
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Amisulpride 300 mg/d
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 2484467

Group type: EXPERIMENTAL
Intervention: MSD vaccine (2 doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pasteur vaccine (3 doses)
Number of subjects: 0
Study: 589786

Group type: EXPERIMENTAL
Intervention: Salbutamol Rotahaler
Number of subjects: 2

Group type: COMPARATOR
Intervention: Conventional pressurized aerosol
Number of subjects: 2
Study: 31296255

Group type: EXPERIMENTAL
Intervention: ARK-Hospital intervention
Number of subjects: 36
Study: 28477702

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training with virtual reality (RAGT+VR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Robot-assisted gait training without virtual reality (RAGT)
Number of subjects: 40
Study: 25486932

Group type: EXPERIMENTAL
Intervention: Medication adherence information (AI) provided to physician
Number of subjects: 1692

Group type: EXPERIMENTAL
Intervention: Medication adherence information (AI) and motivational interviewing (MI)
Number of subjects: 1692

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1692
Study: 23023528

Group type: EXPERIMENTAL
Intervention: Fenretinide 300 mg daily
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Fenretinide (combined groups)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Fenretinide 100 mg daily
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study: 21612949

Group type: EXPERIMENTAL
Intervention: Progressive elastic compression stockings (PECS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Graduated elastic compression stockings (GECS)
Number of subjects: 30
Study: 19224107

Group type: EXPERIMENTAL
Intervention: Standardized cannabis extract containing Delta(9)-THC and cannabidiol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Delta(9)-THC
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Standardized cannabis extract
Number of subjects: 24
Study: 16968803

Group type: EXPERIMENTAL
Intervention: Hook needle insertion under ultrasound guidance
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hook needle insertion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Surgical excision
Number of subjects: 10
Study: 15710069

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day + UDCA 300 mg/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Simvastatin 40 mg/day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day + UDCA 300 mg/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Atorvastatin 40 mg/day
Number of subjects: 48
Study: 11098961

Group type: EXPERIMENTAL
Intervention: Hypocaloric feeding (1 L containing 70 g protein and 1000 kcal)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard weight‐based regimen (25 kcal and 1.5 g protein/kg dry weight)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hypocaloric feeding
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard weight‐based regimen
Number of subjects: 40
Study: 9311395

Group type: EXPERIMENTAL
Intervention: Alfentanil and propofol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Alfentanil, thiopental and suxamethonium
Number of subjects: 80
Study: 8159594

Group type: EXPERIMENTAL
Intervention: Oral cyclosporine in chocolate wafer
Number of subjects: 7

Group type: COMPARATOR
Intervention: Oral cyclosporine mixed with Isocal
Number of subjects: 7

Group type: COMPARATOR
Intervention: Intravenous cyclosporine
Number of subjects: 7
Study: 2851016

Group type: EXPERIMENTAL
Intervention: Enoxaparine 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enoxaparine 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enoxaparine 60 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enoxaparine 80 mg
Number of subjects: 12
Study: 31132209

Group type: COMPARATOR
Intervention: Game-based flexibility training
Number of subjects: 153

Group type: COMPARATOR
Intervention: Game-based inhibition training
Number of subjects: 153

Group type: COMPARATOR
Intervention: Standard training groups
Number of subjects: 153

Group type: COMPARATOR
Intervention: All training groups
Number of subjects: 153

Group type: COMPARATOR
Intervention: Game-based and standard training regimens
Number of subjects: 153
Study: 29890381

Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block (cACB)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Sham catheter
Number of subjects: 165
Study: 28324706

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40IU)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40IU) with positive emotion inductions
Number of subjects: 124

Group type: COMPARATOR
Intervention: Positive emotion inductions (social warmth, pride, neutral)
Number of subjects: 124
Study: 27367855

Group type: EXPERIMENTAL
Intervention: Selenium (200 μg Se as selenized yeast) and Coenzyme Q10 (200 mg) supplementation for four years
Number of subjects: 668

Group type: COMPARATOR
Intervention: Placebo or no treatment
Number of subjects: 668
Study: 23947538

Group type: EXPERIMENTAL
Intervention: Participatory action approach intervention (Bottom-up Innovation project)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Business as usual (control group)
Number of subjects: 0
Study: 22011893

Group type: EXPERIMENTAL
Intervention: 980 nm diode laser irradiation at 1.5 W
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 980 nm diode laser irradiation at 3.0 W
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Non-irradiated roots
Number of subjects: 110

Group type: COMPARATOR
Intervention: Water irrigation
Number of subjects: 110

Group type: COMPARATOR
Intervention: NaOCl irrigation
Number of subjects: 110

Group type: COMPARATOR
Intervention: NaOCl/EDTA irrigation
Number of subjects: 110
Study: 19277942

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) training, 30 Hz, 4 mm amplitude, thrice weekly for 3 min for 4 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) training
Number of subjects: 26
Study: 16881785

Group type: EXPERIMENTAL
Intervention: Relationship enhancing interventions
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Radio and television coverage
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Common selection criteria
Number of subjects: 704
Study: 15015704

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0
Study: 11319936

Group type: EXPERIMENTAL
Intervention: 60-second stretch
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 30-second stretch
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 15-second stretch
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no stretching)
Number of subjects: 62
Study: 9226555

Group type: EXPERIMENTAL
Intervention: Fast atom bombardment mass spectrometry (FAB‐MS) for urinary and faecal porphyrin analysis
Number of subjects: 0
Study: 7959554

Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Preoperative course of chemotherapy and radiotherapy
Number of subjects: 167
Study: 2954497

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clemastine 1 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31678343

Group type: EXPERIMENTAL
Intervention: 10 mg/day vortioxetine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 20 mg/day vortioxetine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 15 mg/day escitalopram
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 29047178

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 27720136

Group type: EXPERIMENTAL
Intervention: Sunitinib plus IMA901 (4·13 mg) and granulocyte macrophage colony-stimulating factor (75 μg), with cyclophosphamide (300 mg/m2) 3 days before the first vaccination.
Number of subjects: 339

Group type: COMPARATOR
Intervention: Sunitinib monotherapy (50 mg orally once daily).
Number of subjects: 339
Study: 24925120

Group type: EXPERIMENTAL
Intervention: Full-dose nuts (50-100 g/d)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Half-dose nuts with half-dose muffins
Number of subjects: 117

Group type: COMPARATOR
Intervention: Full-dose muffins
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Full-dose nuts
Number of subjects: 117
Study: 22133872

Group type: EXPERIMENTAL
Intervention: Responsive Education and Prelinguistic Milieu Teaching (RPMT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Picture Exchange Communication System (PECS)
Number of subjects: 32
Study: 21234859

Group type: EXPERIMENTAL
Intervention: 100 IU/day Vitamin E
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 IU/day Vitamin E
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 300 IU/day Vitamin E
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 19076630

Group type: EXPERIMENTAL
Intervention: Efalizumab, 1 mg/kg/week administered subcutaneously for up to 15 months
Number of subjects: 450
Study: 16189176

Group type: EXPERIMENTAL
Intervention: GH administration alone
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: GH and acipimox co-administration
Number of subjects: 7

Group type: COMPARATOR
Intervention: Acipimox administration
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: GH administration
Number of subjects: 7
Study: 14624289

Group type: EXPERIMENTAL
Intervention: Nimesulide 300 mg
Number of subjects: 114

Group type: COMPARATOR
Intervention: Rofecoxib 25 mg
Number of subjects: 114
Study: 10951149

Group type: EXPERIMENTAL
Intervention: Mite allergen avoidance measures (encasing mattresses and pillows; weekly hot wash of bedding; frequent vacuum cleaning; cleaning/removing soft toys and carpets; no pets allowed)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Allergen avoidance measures (after 12 months for all patients)
Number of subjects: 41
Study: 10160375

Group type: EXPERIMENTAL
Intervention: Ivermectin treatment (five doses in Sierra Leone, three doses in Nigeria)
Number of subjects: 2436

Group type: COMPARATOR
Intervention: Ivermectin treatment
Number of subjects: 2436
Study: 8296531

Group type: EXPERIMENTAL
Intervention: L-threonine at 6 g/day
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 3711553

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) aqueous spray, 42 mcg per spray
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) aerosol spray, 42 mcg per spray
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 44
Study: 29713137

Group type: EXPERIMENTAL
Intervention: Chicago Parent Program (parent group + video; CPP)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Parent Child Interaction Therapy (individualized mastery‐based coaching; PCIT)
Number of subjects: 159
Study: 26763869

Group type: EXPERIMENTAL
Intervention: Family-involved group (FIG)
Number of subjects: 120
Study: 24970291

Group type: EXPERIMENTAL
Intervention: Severe sepsis patients (T1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (T1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Severe sepsis patients (T2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (T2)
Number of subjects: 60
Study: 22095945

Group type: EXPERIMENTAL
Intervention: Rituximab-based regimen
Number of subjects: 30
Study: 19884812

Group type: EXPERIMENTAL
Intervention: Spa therapy (daily local mud packs and bicarbonate-sulfate mineral bath water) for 2 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (routine ambulatory care)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Spa therapy
Number of subjects: 80
Study: 18403998

Group type: EXPERIMENTAL
Intervention: Domiciliary-based nurse-led intervention
Number of subjects: 44
Study: 16194994

Group type: EXPERIMENTAL
Intervention: Active pre‐warming
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Passive pre‐warming
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (pre‐exercise rest)
Number of subjects: 6
Study: 12841542

Group type: EXPERIMENTAL
Intervention: Hyperprolactinemic patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy non‐obese women (control)
Number of subjects: 60
Study: 10807894

Group type: EXPERIMENTAL
Intervention: L/MCT diet (equal quantities of LCT and MCT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: LCT diet (long chain triglycerides)
Number of subjects: 19
Study: 8862439

Group type: EXPERIMENTAL
Intervention: 10, 25, 50, or 75 micrograms/kg/day of rhIL-11 administered subcutaneously for 14 consecutive days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: rhIL-11 treatment at the two highest doses
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: rhIL-11 treatment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: rhIL-11 therapy at the highest dose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: rhIL-11 administration
Number of subjects: 12
Study: 1737653

Group type: EXPERIMENTAL
Intervention: 30-minute upright leg cycling at 50% of peak aerobic capacity
Number of subjects: 22

Group type: COMPARATOR
Intervention: 30-minute control period of rest
Number of subjects: 22
Study: 4091995

Group type: EXPERIMENTAL
Intervention: Meptazinol (200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene/paracetamol mixture (65 mg/650 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene/paracetamol mixture (65 mg/650 mg) + Ethanol (0.8 g kg‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethanol (0.8 g kg‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meptazinol (200 mg) + Ethanol (0.8 g kg‐1)
Number of subjects: 0
Study: 30946121

Group type: EXPERIMENTAL
Intervention: Infection control clinical course for 3 months (experimental group, n = 60)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (n = 70) who did not register for the course
Number of subjects: 130
Study: 30211788

Group type: EXPERIMENTAL
Intervention: Single screw fixation (SS)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Double screw fixation (DS)
Number of subjects: 127
Study: 26959509

Group type: EXPERIMENTAL
Intervention: Early limited ART (initiated at/before 12 weeks)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Deferred continuous ART (initiated after 12 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Uninfected controls
Number of subjects: 38
Study: 24879882

Group type: EXPERIMENTAL
Intervention: Grafts wrapped with rectus muscle fascia
Number of subjects: 36

Group type: COMPARATOR
Intervention: Grafts wrapped with deep temporal fascia
Number of subjects: 36
Study: 22710926

Group type: EXPERIMENTAL
Intervention: Group education modules on early feeding practices (2 modules over 3 months)
Number of subjects: 698

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 698
Study: 20194844

Group type: EXPERIMENTAL
Intervention: Rituximab plus fludarabine and cyclophosphamide (R-FC)
Number of subjects: 552

Group type: COMPARATOR
Intervention: Fludarabine and cyclophosphamide alone (FC)
Number of subjects: 552
Study: 18815396

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase (0.9 mg per kilogram of body weight)
Number of subjects: 821

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 821
Study: 16104444

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional subunit vaccine
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 37
Study: 12607792

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg (for patients weighing <= 30 kg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg (for patients weighing > 30 kg)
Number of subjects: 66
Study: 10372608

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional antipsychotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Novel antipsychotics (olanzapine, quetiapine, risperidone, sertindole, zotepine)
Number of subjects: 0
Study: 7769337

Group type: EXPERIMENTAL
Intervention: Terminal warm blood cardioplegia (TWBC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No terminal warm blood cardioplegia (Control group II)
Number of subjects: 70
Study: 1692948

Group type: EXPERIMENTAL
Intervention: 5 mg sublingual nifedipine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 111940

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 30836031

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study: 28129312

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 1 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 2 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 25810033

Group type: EXPERIMENTAL
Intervention: Health promotion programme
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 23845629

Group type: EXPERIMENTAL
Intervention: Reduced soybean lipid emulsion (1.0 g/kg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard soybean lipid emulsion (3 g/kg/day)
Number of subjects: 28
Study: 21107317

Group type: EXPERIMENTAL
Intervention: Visualization method for benefit-risk assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study
Number of subjects: 0
Study: 19120324

Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL) - V-beam Perfecta, 595 nm, 0.45-1.5 ms
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intense pulsed light (IPL) - StarLux, Lux G prototype handpiece, 500-670 and 870-1400 nm, 5-10 ms
Number of subjects: 20
Study: 17760715

Group type: EXPERIMENTAL
Intervention: H. pylori eradication (omeprazole, amoxicillin, and clarithromycin)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study: 15601558

Group type: EXPERIMENTAL
Intervention: VmP-WBRT (2 cycles of VmP regimen followed by WBRT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: WBRT-VmP (WBRT followed by 2 cycles of VmP regimen)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (WBRT)
Number of subjects: 38
Study: 11467764

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 15314

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 15314
Study: 9569998

Group type: EXPERIMENTAL
Intervention: ABT-761 (10-160 mg)
Number of subjects: 24
Study: 7827746

Group type: EXPERIMENTAL
Intervention: Conforma II mattress overlay
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard hospital mattress
Number of subjects: 30
Study: 2839724

Group type: EXPERIMENTAL
Intervention: Susta II (12.4-g soy polysaccharide/2000 kcal)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Enrich (38.5-g soy polysaccharide/2000 kcal)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Ensure (fiber-free formula)
Number of subjects: 14
Study: 1219276

Group type: EXPERIMENTAL
Intervention: Idulian (syrup) 2 x 0.5 mg
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 31201005

Group type: EXPERIMENTAL
Intervention: HeartMate 3 LVAD
Number of subjects: 0

Group type: COMPARATOR
Intervention: HVAD
Number of subjects: 0

Group type: COMPARATOR
Intervention: HeartMate II
Number of subjects: 0
Study: 31271239

Group type: EXPERIMENTAL
Intervention: Reinforcers (monetary rewards for SMBG and associated behaviors)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Reinforcers
Number of subjects: 60
Study: 28710329

Group type: EXPERIMENTAL
Intervention: Ranolazine (500 mg twice daily, increased to 1,000 mg twice daily after week 2)
Number of subjects: 13
Study: 24156737

Group type: EXPERIMENTAL
Intervention: Poor-effort (treatment) condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Full-effort (control) condition
Number of subjects: 0
Study: 23194432

Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 321

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 321